Workflow
J&J (JNJ) Seeks Expanded Use of Tremfya for Ulcerative Colitis
JNJJ&J(JNJ) Zacks Investment Research·2024-03-12 10:41

Johnson & Johnson (JNJ) has announced the submission of a supplemental biologics license application (sBLA) seeking approval of its immunology medicine, Tremfya, for a new indication — moderately to severely active ulcerative colitis (UC).Tremfya is presently approved to treat certain patients with plaque psoriasis and active psoriatic arthritis in several countries, including the United States and the EU. The sBLA for the UC indication was based on data from the phase III QUASAR study. Data from this study ...